Results 21 to 30 of about 11,553 (254)

Unloading using Impella CP during profound cardiogenic shock caused by left ventricular failure in a large animal model: impact on the right ventricle

Intensive Care Medicine Experimental, 2020
Background and aim This study aimed to assess right ventricular (RV) function during cardiogenic shock due to acute left ventricular (LV) failure, including during LV unloading with Impella CP and an added moderate dose of norepinephrine.
Jakob Josiassen, Ole Kristian Lerche Helgestad, Nanne Louise Junker Udesen, Ann Banke, Peter Hartmund Frederiksen, Janus Adler Hyldebrandt, Henrik Schmidt, Lisette Okkels Jensen, Christian Hassager, Hanne Berg Ravn, Jacob E. Møller   +10 more
doaj   +1 more source

Current management of patients with severe acute peripartum cardiomyopathy: practical guidance from the Heart Failure Association of the European Society of Cardiology Study Group on peripartum cardiomyopathy [PDF]

, 2016
No abstract ...
Arrigo, Biteker, Blauwet, Brignole, Burkhoff, Cecconi, Duncker, Elkayam, Ersbøll, Fett, Fett, Forster, Gevaert, Haghikia, Haghikia, Haghikia, Hilfiker-Kleiner, Hilfiker-Kleiner, Hilfiker-Kleiner, Hilfiker-Kleiner, Kao, Labbene, Levy, Maisch, Masip, McNamara, Mebazaa, Mebazaa, Miller, Mouquet, Napp, Neumann, O'Connor, Patten, Pillarisetti, Ponikowski, Rasmusson, Regitz-Zagrosek, Schroeter, Seyfarth, Slaughter, Sliwa, Sliwa, Sliwa, Stapel, Strueber, Thiele, Thiele, Tibazarwa   +48 more
core   +7 more sources

Mid-term survival in patients awaiting heart and kidney transplantation with Impella 5.5 support. [PDF]

ESC Heart Fail
Abstract Background Patients with end‐stage heart failure and chronic kidney disease requiring dual‐organ transplantation (DOT) face significant challenges in utilizing durable mechanical circulatory support due to the risks associated with renal replacement therapies (RRTs) and multi‐organ failure.
Desai S, Paghdar S, Ruiz J, Jang JM, Malkani S, Yip DS, Leoni J, Nativi J, Sareyyupoglu B, Landolfo K, Pham S, Patel P, Goswami R.   +12 more
europepmc   +2 more sources

The intelligent Impella: Future perspectives of artificial intelligence in the setting of Impella support

ESC Heart Failure
Aims Artificial intelligence (AI) has emerged as a potential useful tool to support clinical treatment of heart failure, including the setting of mechanical circulatory support (MCS).
Filippo Consolo, Jacopo D'Andria Ursoleo, Marina Pieri, Pasquale Nardelli, Lorenzo Cianfanelli, Vittorio Pazzanese, Silvia Ajello, Anna Mara Scandroglio   +7 more
doaj   +3 more sources

A case of left ventricular free wall rupture after insertion of an IMPELLA® left ventricular assist device diagnosed by transesophageal echocardiography

JA Clinical Reports, 2021
Background The IMPELLA® is a minimally invasive left ventricular assist device. We report a case in which transesophageal echocardiography (TEE) was useful in diagnosis of left ventricular rupture after IMPELLA® insertion. Case presentation A 75-year-old
Akito Mizuno, Shuji Kawamoto, Shuji Uda, Kenichiro Tatsumi, Chikashi Takeda, Tomoharu Tanaka, Kazuhiko Fukuda   +6 more
doaj   +1 more source

Temporary circulatory support with surgically implanted microaxial pumps in postcardiotomy cardiogenic shock following coronary artery bypass surgeryCentral MessagePerspective

JTCVS Open, 2023
Objectives: Patients with ischemic cardiomyopathy undergoing coronary artery bypass grafting (CABG) surgery may develop postcardiotomy cardiogenic shock.
Wiebke Sommer, MD, Rawa Arif, MD, Jamila Kremer, MD, Sameer Al Maisary, MD, Markus Verch, MD, Ursula Tochtermann, MD, Matthias Karck, MD, Anna L. Meyer, MD, Gregor Warnecke, MD   +8 more
doaj   +1 more source

Transcaval Access for Impella Placement: A Viable Alternative in Appropriate Patients. [PDF]

J Soc Cardiovasc Angiogr Interv
Reed GW, Kalra A, Zghyer F.
europepmc   +3 more sources

Single center first year experience and outcomes with Impella 5.5 left ventricular assist device

Journal of Cardiothoracic Surgery, 2022
Background The Impella 5.5® was approved by the FDA for use for mechanical circulatory support up to 14 days in late 2019 at limited centers in the United States.
Joanna R. Rock, Cynthia A. Kos, Anthony Lemaire, Hirohisa Ikegami, Mark J. Russo, Danyaal Moin, Kenneth Dulnuan, Deepa Iyer   +7 more
doaj   +1 more source

Complete Revascularisation in Impella-Supported Infarct-Related Cardiogenic Shock Patients Is Associated With Improved Mortality

Frontiers in Cardiovascular Medicine, 2021
Background: Acute myocardial infarction-related cardiogenic shock (AMI-CS) still has high likelihood of in-hospital mortality. The only trial evidence currently available for the intra-aortic balloon pump showed no benefit of its routine use in AMI-CS ...
Andreas Schäfer, Ralf Westenfeld, Jan-Thorben Sieweke, Andreas Zietzer, Julian Wiora, Giulia Masiero, Carolina Sanchez Martinez, Giuseppe Tarantini, Nikos Werner, Nikos Werner   +9 more
doaj   +1 more source

Impella 2.5

Journal of Cardiovascular Translational Research, 2009
Impella 2.5 (Abiomed Inc., Danvers, Ma.) is a percutaneous microaxial circulatory support pump that delivers up to 2.5 l/min of systemic flow augmentation by pumping directly from the left ventricle into the ascending aorta. This article describes the device including the insertion method, fundamental principles of action, and clinical results from the
Daniel H, Raess, David M, Weber
openaire   +2 more sources